Dextech Medical AB
Dextech Medical AB engages in the development of drug candidates with application in urological oncology, primarily prostate cancer. The company's lead candidate, OsteoDex that has completed a phase IIb clinical trial for the treatment of bone metastases in castration-resistant prostate cancer, as well as in preclinical stage to treat breast and lung cancer, as well as multiple myeloma. The compa… Read more
Market Cap & Net Worth: Dextech Medical AB (LQ0)
Dextech Medical AB (F:LQ0) has a market capitalization of $17.36 Million (€16.91 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #29994 globally and #3310 in its home market, demonstrating a -1.61% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Dextech Medical AB's stock price €0.92 by its total outstanding shares 18485857 (18.49 Million).
Dextech Medical AB Market Cap History: 2026 to 2026
Dextech Medical AB's market capitalization history from 2026 to 2026. Data shows growth from $17.36 Million to $17.36 Million (0.00% CAGR).
Dextech Medical AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Dextech Medical AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of LQ0 by Market Capitalization
Companies near Dextech Medical AB in the global market cap rankings as of March 19, 2026.
Key companies related to Dextech Medical AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Dextech Medical AB Historical Marketcap From 2026 to 2026
Between 2026 and today, Dextech Medical AB's market cap moved from $17.36 Million to $ 17.36 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €17.36 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Dextech Medical AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $17.36 Million USD |
| MoneyControl | $17.36 Million USD |
| MarketWatch | $17.36 Million USD |
| marketcap.company | $17.36 Million USD |
| Reuters | $17.36 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.